This report was first published by Endpoints News. To see the original version, click here
Online healthcare provider Hims & Hers said it would start selling a compounded version of Novo Nordisk’s Wegovy pill on Thursday, just a month after the FDA’s approval of the brand-name pill version of the blockbuster weight loss injection.
Hims’ aggressive move is almost certain to prompt efforts by Novo to stop the competing drug, which could undercut sales of what Novo hopes will revive its blockbuster obesity franchise. It also comes with vast implications for other drugmakers and the US system of patents and sales exclusivity, as it suggests that almost any brand-name drug could be under threat from compounded competitors.
您已阅读24%（725字），剩余76%（2282字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。